Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kadcyla and Neratinib for HER2+ Breast Cancer with MRD
NCT05388149Phase 2Recruiting
- Sponsor
- University Health Network
- Start
- Dec 2022
- Primary completion
- Jul 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of neratinib in HER2-positive breast cancer, sponsored by University Health Network. Started Dec 2022; status: recruiting.
02
Drugs
neratinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05388149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05388149.